Keck School of Medicine of USC

Keck School of Medicine of USC

We are dedicated to promoting health, preventing and curing disease, advancing biomedical research and educating tomorrow’s physicians and scientists.

 

Keck School of Medicine of USC
Avatar

2022 Updates on the Adjuvant Treatment of Early Stage HER2+ BC

By Keck School of Medicine of USC FEATURING Joyce O'Shaughnessy
February 14, 2022
3 Comments
Login to view comments. Click here to Login

Featured Video

13:03
Novartis Oncology

CDK4/6 Inhibitor Option for HR+/HER2- mBC: Are All CDK4/6 Inhibitors…

Feat. D. Slamon

Featured Video

22:25
Novartis Oncology

The Importance of Dosing and Patient Adherence in HR+/HER2- mBC

Feat. N. McAndrew
9th Annual USC Multi-Disciplinary Breast Cancer Symposium
30:46
Keck School of Medicine of USC

2022 Updates on the Adjuvant Treatment of Early Stage HER2+ BC

Feat. J. O'Shaughnessy
33:55
Keck School of Medicine of USC

Improving Outcomes for Patients With HR+ BC: From Metastatic to Earl…

Feat. H. Rugo
37:19
Keck School of Medicine of USC

The Past, the Present, and the Future of TNBC: Recent Updates and Mo…

Feat. S. Tolaney
32:59
Keck School of Medicine of USC

I SPY 2.2: Responsive, Adaptive Trial to Prioritize Promising Invest…

Feat. L. Esserman